In conclusion, this study enhanced the understanding of the mechanisms by which inhibition of the CXCR4/PLC pathway improves the efficacy of Dex in the treatment of B-ALL and overcomes resistance. The gene discussed is HSPG2; the disease is acute lymphoblastic leukemia.